<DOC>
	<DOCNO>NCT02874664</DOCNO>
	<brief_summary>Study evaluate effect rovalpituzumab tesirine cardiac ventricular repolarization subject small cell lung cancer ( SCLC ) .</brief_summary>
	<brief_title>A Study Rovalpituzumab Tesirine Study Cardiac Ventricular Repolarization Subjects With Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Histologically cytologically confirm extensivestage smallcell lung cancer ( SCLC ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . Adequate hematologic organ function confirm laboratory value Clinically significant cardiac abnormality include QRS duration &gt; 120 msec ; QTcF &gt; 470 msec woman &gt; 450 msec men ; Abnormal cardiac rhythm ; Clinically significant cardiac valve abnormality ; Documented history leave ventricular ejection fraction &lt; 0.30 within 6 month ; Permanent pacemaker automatic implantable cardioverter defibrillator ; History torsades de pointes , congenital long QT syndrome , family history long QT syndrome sudden death Recent ongoing serious infection Women pregnant breastfeed Prior exposure pyrrolobenzodiazepine ( PBD ) base drug , prior participation rovalpituzumab tesirine clinical trial , know hypersensitivity rovalpituzumab tesirine excipient contain drug formulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>